Dezhou Bocheng Pharmacy Co. Ltd.

The pharmacokinetic parameters were used as the primary endpoints to compare the pharmacokinetic behavior of the test preparation, empagliflozin tablets (licensed by: Dezhou Bocheng Pharmaceutical Co., Ltd.) and the reference preparation, empagliflozin tablets (licensed by: Boehringer Ingelheim International GmbH, trade name: Otangjing®) in healthy subjects after oral administration in the fasting/postprandial state, and to evaluate the bioequivalence of the two preparations. The safety of the test preparation, empagliflozin tablets, and the reference preparation, empagliflozin tablets, in healthy subjects was observed.

The metformin hydrochloride sustained-release tablets (specification: 1000 mg) produced by Dezhou Bocheng Pharmaceutical Co., Ltd. were used as the reference preparation, and the pharmacokinetic parameters were used as indicators to compare the bioequivalence of the two preparations and evaluate the in vivo safety of the two preparations.

Main purpose: Using pharmacokinetic parameters as the primary endpoint evaluation indicators, the pharmacokinetic behavior of the test preparation nifedipine sustained-release tablets (II) (manufacturer: Dezhou Bocheng Pharmaceutical Co., Ltd.) and the reference preparation nifedipine sustained-release tablets (manufacturer: Bayer PharmaAG, trade name: Adalat® retard) in healthy subjects after oral administration in the fasting/postprandial state was compared to evaluate the bioequivalence of the two preparations. Secondary purpose: To observe the safety of the test preparation nifedipine sustained-release tablets (II) and the reference preparation nifedipine sustained-release tablets in healthy subjects.